Evolent Health, Inc.
$1.31B- Market cap
- $489.55M
- Debt
- +$970.54M
- Cash
- −$151.86M
Capital structure 34% equity / 66% debt · EV / Revenue 0.70x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: EVH stock price at discount vs PRGO $4.33 current versus $8.08 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PRGO's multiple
Implied fair value · at EVH's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EVH FY 2025 (ended Dec 31, 2025) · PRGO FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 34% equity / 66% debt · EV / Revenue 0.70x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 36% equity / 64% debt
PRGO carries the larger enterprise value at $5.71B against $1.31B; EVH trades on the lower EV / Revenue multiple (0.70x vs 1.34x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Evolent Health, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Perrigo Company plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
2.34x
1.24x
Net debt / EBITDA
Leverage against operating earnings
-2.11x
—
Cash and equivalents
Liquid reserves on the balance sheet
$151.86M
—
Total debt
Interest-bearing obligations outstanding
$970.54M
$3.64B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cigna Group
EVH vs CI
MOLINA HEALTHCARE, INC.
EVH vs MOH
Teladoc Health, Inc.
EVH vs TDOC
CLOVER HEALTH INVESTMENTS, CORP. /DE
EVH vs CLOV
UNITEDHEALTH GROUP INC
EVH vs UNH
TEVA PHARMACEUTICAL INDUSTRIES LTD
EVH vs TEVA
Organon & Co.
EVH vs OGN
Hims & Hers Health, Inc.
EVH vs HIMS
HERBALIFE LTD.
EVH vs HLF
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EVH can stabilize revenue after the 26.6% decline and avoid further balance-sheet deterioration, then a modest long position can be justified because the stock still trades below the P/S-implied value and inside its historical band; otherwise, the weak growth and distress signals argue for caution.
EVH’s current price of $5.71 sits below the implied price of $6.03 on the P/S basis, suggesting about 5.5% upside. The stock is also trading within its historical band, which points to a relatively modest valuation gap rather than a deep discount.
Supporting Metrics